Trial Profile
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary) ; Ropidoxuridine
- Indications Prostate cancer
- Focus Diagnostic use
- 13 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 13 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 27 Jan 2024 Results presented at the 2024 Genitourinary Cancers Symposium